These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 28164528)
1. Screening for BCR-ABL1 in Patients with an Isolated Eosinophilia. Langabeer SE Clin Lab; 2016 Oct; 62(10):2073-2074. PubMed ID: 28164528 [No Abstract] [Full Text] [Related]
3. Characterization of a novel variant BCR-ABL1 fusion transcript in a patient with chronic myeloid leukemia: Implications for molecular monitoring. Crampe M; Haslam K; Kelly J; Conneally E; Langabeer SE Hematol Oncol Stem Cell Ther; 2017 Jun; 10(2):85-88. PubMed ID: 27013275 [TBL] [Abstract][Full Text] [Related]
4. Chronic Myeloid Leukemia With Rare Variant b2a3 (e13a3) BCR-ABL1 Fusion. Ha J; Cheong JW; Shin S; Lee ST; Choi JR Ann Lab Med; 2016 May; 36(3):287-9. PubMed ID: 26915625 [No Abstract] [Full Text] [Related]
5. Unusual location of BCR-ABL1 fusion sequences in a chronic myeloid leukemia patient. Zámečníkova A; Al Bahar S; Pandita R Hematology; 2012 Nov; 17(6):321-4. PubMed ID: 22989955 [TBL] [Abstract][Full Text] [Related]
6. Extramedullary BCR-ABL1-negative myeloid leukemia in a patient with chronic myeloid leukemia and synchronous cytogenetic abnormalities in Philadelphia-positive and -negative clones during imatinib therapy. Quintás-Cardama A; Kantarjian H; Abruzzo LV; Cortes J Leukemia; 2007 Nov; 21(11):2394-6. PubMed ID: 17690707 [No Abstract] [Full Text] [Related]
7. CALR-mutated primary myelofibrosis evolving to chronic myeloid leukemia with both CALR mutation and BCR-ABL1 fusion gene. Diamond JM; de Almeida AM; Belo HJ; da Costa MP; Cabeçadas JM; Abecasis MM Ann Hematol; 2016 Dec; 95(12):2101-2104. PubMed ID: 27699446 [No Abstract] [Full Text] [Related]
8. Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing. Linhartova J; Hovorkova L; Soverini S; Benesova A; Jaruskova M; Klamova H; Zuna J; Machova Polakova K Mol Cancer; 2015 Apr; 14():89. PubMed ID: 25928096 [TBL] [Abstract][Full Text] [Related]
9. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia. Moore FR; Yang F; Press RD Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688 [TBL] [Abstract][Full Text] [Related]
10. Concurrence of e1a2 and e19a2 BCR-ABL1 Fusion Transcripts in a Typical Case of Chronic Myeloid Leukemia. Lee J; Kim DS; Lee HS; Choi SI; Cho YG Ann Lab Med; 2017 Jan; 37(1):74-76. PubMed ID: 27834071 [No Abstract] [Full Text] [Related]
11. Standardized Molecular Monitoring for Variant BCR-ABL1 Transcripts in Chronic Myeloid Leukemia. Langabeer SE Arch Pathol Lab Med; 2015 Aug; 139(8):969. PubMed ID: 26230589 [No Abstract] [Full Text] [Related]
12. [Chronic myelogenous leukemia expressing two bcr-abl chimeric mRNA; a case report]. Hashimoto S; Hiyoshi M; Hino M; Yamane T; Ota T; Koh KR; Tagawa S; Tatsumi N Rinsho Ketsueki; 1997 Jan; 38(1):72-4. PubMed ID: 9028165 [TBL] [Abstract][Full Text] [Related]
14. A novel aberrant form of e13a2 BCR-ABL1 transcript in chronic myelogenous leukemia undetectable with the standardized real-time quantitative polymerase chain reaction from the Europe Against Cancer Program. Matsushita H; Yamamoto M; Tsuboi K; Masukawa A; Arakawa S; Asai S; Ogawa Y; Ando K; Miyachi H Clin Chem Lab Med; 2009; 47(7):885-7. PubMed ID: 19575551 [No Abstract] [Full Text] [Related]
15. Coexistence of different clonal populations harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib. Agirre X; Román-Gómez J; Vázquez I; Jiménez-Velasco A; Larráyoz MJ; Lahortiga I; Andreu EJ; Márquez J; Beltrán de Heredia JM; Odero MD; Prósper F; Calasanz MJ Cancer Genet Cytogenet; 2005 Jul; 160(1):22-6. PubMed ID: 15949566 [TBL] [Abstract][Full Text] [Related]
16. Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia. Loncarevic IF; Römer J; Starke H; Heller A; Bleck C; Ziegler M; Fiedler W; Liehr T; Clement JH; Claussen U Genes Chromosomes Cancer; 2002 Jun; 34(2):193-200. PubMed ID: 11979553 [TBL] [Abstract][Full Text] [Related]
17. e6a2 BCR/ABL1 fusion with cryptic der(9)t(9;22) deletions in a patient with chronic myeloid leukemia. Roti G; La Starza R; Gorello P; Gottardi E; Crescenzi B; Martelli MF; Mecucci C Haematologica; 2005 Aug; 90(8):1139-41. PubMed ID: 16079118 [TBL] [Abstract][Full Text] [Related]
18. Molecular response to imatinib in chronic myeloid leukaemia with a variant e13a3 BCR-ABL1 fusion. McCarron SL; Langabeer SE; Bolger K; Haslam K; Crampe M; Kelly J; Morrell R Med Oncol; 2015 Feb; 32(2):452. PubMed ID: 25579165 [TBL] [Abstract][Full Text] [Related]
19. High frequency of BTG1 deletions in patients with BCR-ABL1-positive acute leukemia. Xie J; Wang Q; Wang Q; Yao H; Wen L; Ma L; Wu D; Chen S Cancer Genet; 2014 May; 207(5):226-30. PubMed ID: 24998463 [TBL] [Abstract][Full Text] [Related]